Baylor College of Medicine

Phase 1 Clinical Trial for Childhood Obesity Treatment with Tirzepatide! (H-53214)




In response to the growing concern surrounding childhood obesity, we are thrilled to introduce a Phase 1 FDA-regulated clinical trial aimed at assessing the safety and tolerability of Tirzepatide. This phase marks a significant stride in our mission to combat childhood obesity and mitigate the related health risks.

Who is eligible to participate?

  • Children between 6-11 years old
  • Maximum weight allowed is 110 pounds
  • BMI percent equal or exceeds the 95th percentile

Benefits of Participation:

  • Contribute to pioneering research.
  • Receive complimentary support sessions.
  • Compensation of up to $1,400 over a 14-18 weeks duration of study participation.

Your Participation Matters:

By enrolling in this study, you assume a pivotal role in advancing our comprehension of childhood obesity and its potential treatments. We are wholeheartedly dedicated to making a positive impact on the lives of children and their families, and your contribution can play a part in shaping the future of healthcare.

To get in touch with us, please complete our contact form below or reach out to us at (713) 798-9316 or

Complete our Study Interest Contact Form:

IRB: H-53214




Back to topback-to-top